Search

Find exactly what you’re looking for.
Search

Service
Showing 61-80 of 184 results

Developing a Corporate AI Policy Join Association of Corporate Counsel, along with inside and outside counsel presenters, as they discuss implementing best practices and responsible use policies to manage the risk of utilizing AI in the workplace. Speakers: Matthew Kohel, Partner, Intellectual...

Please join us for an upcoming tech M&A workshop, Selling Up Selling Out: Live in Minneapolis, organized by Corum Group at our offices on Wednesday, August 9th. Saul Ewing LLP is sponsoring the half-day conference, where you can hear from former CEOs and market experts as they cover valuations...

Since Elon Musk announced his decision to remove the iconic bird logo and adopt "X", as Twitter's new logo (the "X Logo"), the rebranding decision has been the talk of the town. The rollout has prompted a barrage of reactions and has many questioning whether the change will attract legal hurdles...

A recently filed class action lawsuit raises more legal challenges to providers of generative artificial intelligence (AI) tools that are used to create content. The suit cautions that a doomsday scenario is approaching and alleges a host of privacy and other violations occurring along the way. What...

NEW YORK, NY, (June 27, 2023) – In joining Saul Ewing as a new partner, Peri Berger will represent clients facing complex commercial disputes involving breach of contract, fraud, business ownership and control, intellectual property, trade secrets and other threats related to their operations in...

On June 8, 2023, the Supreme Court issued a unanimous decision in Jack Daniel’s Properties, Inc. v. VIP Products LLC, 599 U.S. ---, 2023 WL 3872519, reversing VIP Products’ victory in a trademark case against Jack Daniel’s, and remanding to the Arizona District Court for further proceedings. What...

​On May 18, 2023, the Supreme Court unanimously affirmed the Federal Circuit's decision, Amgen Inc. v. Sanofi, 987 F.3d 1080 (Fed. Cir. 2021), that the claims of two of Amgen's patents were invalid for lack enablement. The involved patents, US 8,829,165 and US 8,859,741, are directed to monoclonal...

For More Information
Contact us